La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Rohto PharmaceuticalLtd Bilan de santé

Santé financière contrôle des critères 5/6

Rohto PharmaceuticalLtd possède un total de capitaux propres de ¥257.2B et une dette totale de ¥45.9B, ce qui porte son ratio d'endettement à 17.8%. Son actif total et son passif total sont ¥408.7B et de ¥151.5B. L'EBIT de Rohto PharmaceuticalLtd est ¥40.3B ce qui fait que son ratio de couverture des intérêts -20.7. Elle dispose de liquidités et de placements à court terme de ¥73.6B.

Informations clés

17.8%

Ratio d'endettement

JP¥45.87b

Dette

Ratio de couverture des intérêts	-20.7x
Argent liquide	JP¥73.62b
Fonds propres	JP¥257.25b
Total du passif	JP¥151.49b
Total des actifs	JP¥408.73b

Mises à jour récentes de la santé financière

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Recent updates

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4527 ( ¥211.7B ) dépassent ses passifs à court terme ( ¥119.5B ).

Passif à long terme: Les actifs à court terme de 4527 ( ¥211.7B ) dépassent ses passifs à long terme ( ¥31.9B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4527 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4527 est passé de 3.3% à 17.8% au cours des 5 dernières années.

Couverture de la dette: La dette de 4527 est bien couverte par le flux de trésorerie opérationnel ( 74.7% ).

Couverture des intérêts: 4527 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Rohto PharmaceuticalLtd Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Recent updates

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Consensus forecasts updated

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Price target increased to JP¥4,325

Now 21% undervalued

Upcoming dividend of JP¥21.00 per share

Now 20% undervalued

Price target increased to JP¥4,175

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings released: EPS JP¥52.82 (vs JP¥37.18 in 2Q 2021)